1/53
Looks like no tags are added yet.
Define asthma
Heterogeneous chronic airway inflammation with symptoms that fluctuate and a reversible limitation of expiratory flow.
True or False: Asthma is reversible either on its own or after therapy.
True
Explain how inflammation narrows the airway.
Smooth muscle tightens and mucus production increases.
Describe the role of bronchial hyperresponsiveness.
It heightens the tendency for the airway to narrow.
Name four structural changes seen with long‑standing inflammation.
- Fibrotic extracellular matrix
- augmented smooth muscle contraction
- enlarged mucus glands
- new vessel formation.
Explain the concept of abnormal healing asthma
Repair processes are altered, promoting fixed changes in the airway wall.
Name the immunoglobulin that initiates the cascade in the acute phase of asthma
IgE.
Identify the two sentinel cells first activated.
Mast cells and macrophages.
List mediators released early in the process.
- Histamine
- eicosanoids
- reactive oxygen species.
Describe the immediate functional effects of acute mediators.
Airway muscle contracts, mucus is secreted, and edema develops.
Specify the granulocyte that is a hallmark of type‑2 airway inflammation.
Eosinophils.
Identify the T‑helper subset linked to protective immunity.
Th1.
Identify the T‑helper subset linked to allergic inflammation.
Th2.
State what mast cells do during chronic disease activity.
They degranulate and release cytokines and leukotrienes
Explain how macrophages contribute to amplification.
They digest microbes and further drive the inflammatory response.
Map inflammatory driver to anti‑inflammatory drug class.
Eosinophilic inflammation corresponds to inhaled corticosteroids.
Map bronchoconstriction to rapid bronchodilator target.
β‑adrenergic receptors correspond to β‑agonists.
List two additional biologic targets beyond steroids and β‑agonists.
Interleukins and IgE.
State the two core components needed for diagnosis.
Characteristic symptom patterns along with variable limitation of expiratory flow.
List frequent symptoms reported by patients.
- Wheezing
- breathlessness
- cough
- chest tightness.
Describe temporal features typical of symptoms.
Worse at night or on waking, vary in intensity and frequency, and often triggered.
List family/past history elements that raise suspicion.
Allergy, asthma in relatives, allergic rhinitis, and atopic dermatitis.
Identify the preferred test for airflow assessment.
Spirometry is preferred over peak flow.
State the ratio that indicates obstruction in adults.
FEV1/FVC < 0.75-0.8
State the ratio that indicates obstruction in children.
FEV1/FVC < 0.9
Describe patterns that demonstrate excessive variability.
Improvement after treatment, decline after exertion, or differences across visits.
Provide the numerical criterion for reversibility using FEV1.
At least a 20% and 200 mL rise from baseline.
Provide the numerical criterion for reversibility using peak flow.
At least a 20% rise.
Describe the typical finding on chest auscultation during expiration.
Wheezes that can require forced exhalation to detect and may disappear during severe attacks.
Identify findings not characteristic of asthma
Crackles and inspiratory wheezes as primary features.
List upper airway findings that may coexist.
Signs of allergic rhinitis or nasal polyps.
State an important step when evaluating the patient beyond exam.
Exclude alternative diagnoses.
Name tests that assess airway hyperresponsiveness.
Challenge procedures such as methacholine, histamine, exercise, hyperventilation, or mannitol.
State how challenge tests perform diagnostically.
Moderately sensitive with limited specificity, better for exclusion than confirmation.
Identify two forms of allergy testing used.
Skin prick and serum immunoglobulin E assays.
List imaging's role in this disease.
Evaluate comorbidities, rule out alternative conditions, and find congenital issues.
State how exhaled nitric oxide relates to airway inflammation.
Only modestly linked to eosinophils and insufficient for ruling in or out.
Describe features of the allergic phenotype.
Early onset with personal or family atopy and eosinophilic airway inflammation; typically responsive to inhaled corticosteroids.
Identify the demographic more likely to first present in adulthood.
Women.
State key points for adult‑onset asthma
- Initial presentation later in life
- non‑allergic pattern possible
- higher steroid dose needs
- consideration of work‑related causes.
Describe the non‑allergic asthma
- Later development or persistence from childhood with neutrophilic, eosinophilic, or few inflammatory cells
- shows less immediate steroid response.
Describe persistent airflow limitation asthma
Longstanding disease with incompletely reversible obstruction likely due to structural change.
Describe obesity‑related phenotype.
Prominent respiratory complaints with minimal eosinophilic inflammation.
Describe cough‑predominant phenotype.
Cough is the only symptom and variable flow limitation is absent.
Specify the drop in FEV1 used to define exertional airway narrowing.
10% or greater fall from baseline.
Name typical provoking conditions for exertional airway narrowing.
Cold and dry air as well as airborne allergens.
Describe the diurnal pattern of pulmonary function in asthma
A significant decline occurs overnight with the lowest point around 3-4 am
List contributors that can precipitate nighttime worsening.
- Allergens
- ambient factors
- gastroesophageal reflux
- obstructive sleep apnea,
- sinus disease.
Explain the clinical relevance of nocturnal worsening of asthma
It signals disease severity and poor control.
Summarize the diagnostic strategy in one line.
Combine symptom patterns with variable expiratory flow limitation; there is no single definitive test.
State a prevention takeaway regarding mortality.
Improved care and education can avert most deaths.
Link cellular driver to preferred controller therapy.
Eosinophilic inflammation suggests inhaled corticosteroids.
Link receptor physiology to rescue therapy.
β‑receptors on airway smooth muscle are targeted with β‑agonists.
Name two biologic‑level targets.
Type‑2 interleukins and IgE.